Connect with us

Entrepreneur

Lab-grown human eggs and sperm ‘about seven years away’

Published

on

Scientists say lab-grown human sex cells could be less than a decade from reality, with major implications for fertility and reproduction.

The technology could, in theory, allow anyone to have biological children, regardless of sex, fertility or age.

Researchers are making rapid progress towards turning adult skin or blood cells into eggs and sperm through a process known as in-vitro gametogenesis (IVG) – a method that reprogrammes cells genetically to become gametes.

The technique typically starts by converting adult cells into stem cells, which are then guided into becoming primordial germ cells – the precursors to eggs and sperm.

These are placed inside a lab-grown organoid (a miniature version of an organ), which provides the biological signals needed to develop them further.

Prof Katsuhiko Hayashi, a developmental geneticist at the University of Osaka, told a meeting of the European Society of Human Reproduction and Embryology in Paris this week that his lab is about seven years away from creating viable human sperm.

Other frontrunners include a team at the University of Kyoto and California-based startup Conception Biosciences, whose Silicon Valley backers include OpenAI founder Sam Altman.

Conception’s chief executive told the Guardian the company is focused on producing clinical-grade human eggs and believes the technology could reverse population decline and open the door to human gene editing.

Hayashi said: “I feel a bit of pressure. It feels like being in a race.

“On the other hand, I always try to persuade myself to keep to a scientific sense of value.”

Hayashi’s lab has already produced baby mice with two biological fathers, suggesting the technique could one day be used by same-sex couples.

He said the lab receives emails from prospective fertility patients about once a week.

He said: “We get emails from [fertility] patients, maybe once a week.

“Some people say: ‘I can come to Japan.’ So I feel the demand from people.”

Matt Krisiloff, chief executive of Conception Biosciences, said: “Just the aspect alone of pushing the fertility clock … to potentially allow women to have children at a much older age would be huge.

“Outside of social policy, in the long term this technology might be the best tool we have to reverse population decline dynamics due to its potential to significantly expand that family planning window.”

Hayashi presented his team’s latest progress at the event, including the creation of primitive mouse sperm inside a lab-grown testicle organoid measuring about 1mm across, and the development of a human ovary organoid – a step towards growing human eggs in the lab.

Inside the artificial testes, Hayashi’s team managed to grow spermatocytes – the precursors of sperm cells – before the cells died.

He said an updated version of the organoid with a better oxygen supply could allow the cells to reach maturity.

Hayashi estimated that viable lab-grown human sperm could be about seven years away.

Creating sperm from female cells, he said, would be “technically challenging, but I don’t say it is impossible.”

He also suggested that his former colleague Prof Mitinori Saitou, based at Kyoto University, or Conception Biosciences could be ahead in the race.

“But they [Conception] are really, really secretive,” he added.

Others agreed with Hayashi’s timescale.

“People might not realise how quickly the science is moving,” said Prof Rod Mitchell, research lead for male fertility preservation in children with cancer at the University of Edinburgh.

“It’s now realistic that we will be looking at eggs or sperm generated from immature cells in the testicle or ovary in five or 10 years’ time.

“I think that is a realistic estimate rather than the standard answer to questions about timescale.”

Prof Allan Pacey, professor of andrology and deputy vice-president at the University of Manchester, said: “I think somebody will crack it. I’m ready for it. Whether society has realised, I don’t know.”

While several labs have successfully produced baby mice from lab-grown eggs, producing viable human eggs has been far more technically difficult.

A recent breakthrough in understanding how eggs stay dormant in the ovary for years could prove key.

Krisiloff declined to share detailed updates but said the company is “making really good progress on getting to a full protocol”.

In the best case, he said, the technology could reach the clinic within five years – though it may take longer.

Most researchers believe years of testing would be required to ensure that lab-grown cells do not carry genetic mutations that could be passed to embryos and future generations.

Some mice created using lab-grown cells have lived normal lifespans and been fertile.

Hayashi said: “We really need to prove that this kind of technology is safe.

“This is a big obligation.”

In the UK, using lab-grown eggs or sperm in fertility treatment is currently illegal.

The Human Fertilisation and Embryology Authority is already considering how safety could be ensured and what testing would be needed before clinical use could be approved.

Mitchell said:“The idea that you can take a cell that was never supposed to be a sperm or an egg and make it into a sperm or an egg is incredible.

“But it does bring the problem of safety. We need to be confident that it’s safe before we could ever use those cells to make a baby.”

News

Sun Pharma to acquire Organon in US$11bn deal

Published

on

Indian pharmaceutical giant Sun Pharma has agreed to buy Organon for US$11.75bn in a deal aimed at expanding its women’s health and biosimilars business.

Organon, which was spun out of Merck in 2021, has built a portfolio of more than 70 women’s health and general medicines products, including biosimilars, sold in the US and about 140 other countries.

The acquisition would give Sun Pharma a broader presence in biosimilars, which are medicines designed to be highly similar to existing biological drugs, and strengthen its position in women’s health.

Dilip Shanghvi, executive chairman of Sun Pharma, said: “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”

The companies said the combined business would generate annual revenue of US$12.4bn, operate across 150 countries and rank among the top three companies globally in women’s health.

They also said it would become the seventh largest biosimilar player.

Sun Pharma said the deal would help grow its innovative medicines business and expand its biosimilars offering.

It added that the combined company would have 18 large markets each generating more than US$100m in revenue.

Organon’s largest markets include the US, Brazil, Canada, China and countries in the European Union. The company also has six manufacturing facilities across the EU and emerging markets.

The deal follows market speculation that began on 10 April, when Indian media reported that Sun Pharma had submitted an all-cash offer for Organon.

A later report said the offer had been revised to US$13bn. Sun Pharma shares rose about 7 per cent on India’s National Stock Exchange after the announcement.

Sun Pharma said it would acquire all of Organon’s issued and outstanding shares in cash, using a combination of available cash and committed bank financing. It also estimated synergies of about US$350m within two to four years of completion.

The company said the acquisition would strengthen its cash generation, with EBITDA and cash flow set to nearly double, supporting efforts to reduce the net debt to EBITDA ratio of 2.3 times resulting from the deal. EBITDA is a measure of operating performance before certain costs are deducted.

Organon reported revenue of US$6.2bn last year and adjusted EBITDA of US$1.9bn. It also reported debt of US$8.64bn, down from US$9.5bn when it separated from Merck, and a cash balance of US$574m.

In November, Organon announced plans to sell its JADA System, designed to control and treat abnormal postpartum uterine bleeding or haemorrhage, to Laborie Medical Technologies for up to US$465m. Net proceeds from the sale will contribute to Organon’s cash balance as of 31 March 2026.

Organon will merge with a subsidiary of Sun Pharma, with Organon surviving the merger. The boards of both companies have approved the transaction.

Carrie Cox, executive chair of Organon, said: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.”

The transaction is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.

Continue Reading

Entrepreneur

Women’s digital health market set to reach US$5.28 billion in 2026 – report

Published

on

The women’s digital health market is set to reach US$5.28bn in 2026, up from US$4.36bn in 2025, according to a new report.

That would represent annual growth of 20.9 per cent, driven by factors including greater smartphone use among women, wider uptake of telehealth and a stronger focus on preventive care.

The report said the market could reach US$11.47bn by 2030, with projected annual growth of 21.4 per cent over the forecast period.

It also pointed to rising awareness of gender-specific health needs, expansion among digital health start-ups, growing demand for personalised healthcare, investment in femtech innovation and the spread of AI-enabled diagnostics.

Wearables linked to health apps and wider use of remote monitoring tools are also expected to play a larger role, as companies focus on more preventive and joined-up care.

Smartphone use was highlighted as a major driver because mobile apps are increasingly being used for women’s health services, from menstrual cycle tracking to pregnancy support.

The report cited Eurostat data showing that in 2023, 89 per cent of EU residents aged 16 to 74 in urban areas accessed the internet via smartphones.

The report also said companies in the sector are developing new technology aimed at improving access to more personalised healthcare.

One example it gave was a 2024 collaboration between Algorand and the Self-Employed Women’s Association to launch a digital health passport for women in India’s informal economy using blockchain technology.

Recent mergers and acquisitions were also noted. In March 2023, Maven Clinic acquired Naytal to expand its services in the UK and Europe.

North America was identified as the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Companies named as key players included Flo Health Inc, Natural Cycles, Elvie, Bellabeat, Clue by Biowink, MobileODT Ltd., Glow, Veera Health, Biowink GmbH, Ava AG, Hims & Hers Health, Inc., The Women’s Wellness Centre, Elara Health, myGynaeDoc, Maven Clinic, Kindbody, Allara Health, Tia and Hera Med Ltd.

Continue Reading

Entrepreneur

Future Fertility raises Series A financing to scale AI tools redefining fertility care worldwide

Published

on

Future Fertility Inc. has announced the closing of a US$4.1 million Series A financing round.

The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners, with participation from new investors Sandpiper Ventures, Gaingels, and Jolt VC.

The financing will accelerate Future Fertility’s commercial expansion into Asia-Pacific and support its entry into the United States, including planned FDA 510(k) clearance for additional products as part of a broader U.S. market entry strategy.

Proceeds will also advance the development of a broader AI platform, from egg assessment through to embryo transfer, designed to support clinicians, embryologists, and patients across the full IVF journey.

M Ventures and Whitecap have supported Future Fertility’s mission to translate AI innovation into meaningful clinical outcomes since the company’s earliest stages.

Oliver Hardick, investment director, M Ventures, said: “Future Fertility is addressing a critical unmet need in reproductive medicine with a differentiated AI platform grounded in clinical data and real-world workflow integration.

“We are excited to continue supporting the company and team because we believe its technology has the potential to improve decision-making for clinicians, bring greater clarity to patients, and help advance a more personalised standard of care in fertility treatment.”

Future Fertility’s AI platform addresses a long-standing gap in fertility care: historically, there has been no objective, clinically validated method for assessing egg quality (Gardner et al., 2025), despite it being one of the most important drivers of reproductive success.

The company’s suite of deep learning tools includes VIOLET™, MAGENTA™, and ROSE™, purpose-built for egg freezing, IVF, and egg donation respectively.

The tools are based on AI models trained and validated on more than 650,000 oocyte images and are deployed in over 300 clinics across 35 countries.

Rhiannon Davies, founding and managing partner, Sandpiper Ventures, said:  “The best outcomes in fertility care globally come from better data and smarter tools. Future Fertility understands that, and they’ve built a platform that delivers on it.

“Sandpiper is proud to back a team turning rigorous science into real results for patients and clinicians alike.”

Partnerships with the world’s leading fertility networks – including IVI RMA and Eugin Group across Latin America and Europe, FertGroup Medicina Reproductiva in Brazil, and most recently announced Kato Ladies Clinic in Japan –  reflect growing demand for objective, AI-powered oocyte assessment in fertility care. In the United States, ROSE™ is newly available under an FDA 513(g) determination.

Research shows that approximately 50 per cent of IVF patients do not understand their likelihood of success, and many discontinue treatment prematurely, even though cumulative success rates improve significantly with multiple cycles (McMahon et al., 2024).

By delivering earlier clarity on egg quality, Future Fertility’s tools support more informed conversations between clinicians and patients, helping set realistic expectations and guide decisions about next steps.

Future Fertility’s growing evidence base spans seven peer-reviewed publications in Human Reproduction, Reproductive BioMedicine Online, Fertility & Sterility, and Nature’s Scientific Reports, and more than 70 scientific abstracts accepted and presented with partner clinics at conferences worldwide.

Christine Prada, CEO, Future Fertility, said: “Fertility treatment is one of the most emotionally and physically demanding experiences a person can go through.

“Every patient deserves objective data, not just a best guess, to support better decisions at critical moments in their care.

“This funding means we can bring that clarity to more patients, in more countries, at a moment when it matters most.”

Find out more about Future Fertility at futurefertility.com

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.